The EED Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal pool with targeted EED gene disruption in the HT29 colorectal adenocarcinoma cell line, providing a heterogeneous loss-of-function model that circumvents clonal selection biases.
The HT29 line is a widely used epithelial model from human colorectal adenocarcinoma, characterized for colorectal cancer biology, intestinal epithelial function, and therapeutic responses. Its defined growth properties and drug sensitivity profiles are ideal for dissecting epigenetic mechanisms in tumorigenesis.
EED is a core Polycomb repressive complex 2 (PRC2) subunit, essential for EZH2 methyltransferase activity and deposition of the repressive mark H3K27me3. It forms critical interactions with EZH2, SUZ12, RBBP4/7, AEBP2, and JARID2, and allosterically regulates EZH2 upon binding to H3K27me3, propagating repressive chromatin domains at loci such as CDKN2A and HOX gene clusters. EED function is influenced by upstream transcriptional regulators including MYC and E2F, and by AKT pathway signaling. Disruption of EED abolishes PRC2 catalytic activity, derepressing tumor suppressor genes and altering expression of factors controlling differentiation and epithelial-mesenchymal transition.
In HT29 colorectal cancer cells, PRC2-mediated H3K27me3 is critical for maintaining the balance between proliferation and differentiation. EED knockout disrupts this epigenetic landscape, leading to derepression of tumor suppressors like CDKN2A and altered expression of lineage-specifying HOX genes, potentially restoring epithelial differentiation and attenuating malignant phenotypes. This model thus provides a physiologically relevant system for dissecting PRC2 dysregulation in colorectal cancer and for exploring the consequences of EED inhibition in this tumor context.
This knockout cell pool is suitable for a broad array of downstream applications, including chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K27me3 occupancy, western blotting for EED, EZH2, and global H3K27me3 levels, and RT-qPCR or RNA-seq to quantify transcriptomic changes in PRC2 targets such as CDKN2A. Functional studies may employ proliferation assays (MTS, clonogenic), differentiation marker analysis, and chemosensitivity screening with EED inhibitors (e.g., A-395) or EZH2 inhibitors (e.g., tazemetostat) to validate drug targets and resistance mechanisms. The model further supports investigation of epigenetic regulatory networks in colorectal cancer, stem cell maintenance, and senescence. For additional information and technical support, please contact Ascent Research.
